Market Overview

UPDATE: FDA Advisory Panel Acting Chairperson Says panel Members Generally Agree that Signal of Cardiovascular Risk Was Seen For Novo Nordisk's Degludec Insulin, and That it "May or May Not Be a Real" Risk -Reuters

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK
RECENT PRO ALERTS

Posted-In: News FDA

 

Related Articles (NVO)

Around the Web, We're Loving...

Get Benzinga's Newsletters